We also observed a statistically insignificant decrease in MMP-9 in healthy women after WBC application (from 437.98 ± 108.43 ng/mL to 385.96 ± 88.63 ng/mL) but the intervention did not significantly impact on the level of MMP-9 in females with MS. This evidence concerns the gene MMP9 and myeloid sarcoma.